PedAM
Pediatric Disease Annotations & Medicines
| Disease | pancreatic cancer |
| Phenotype | C0011860|type 2 diabetes |
| Sentences | 9 |
| PubMedID- 25576058 | Metformin treatment is associated with a decreased risk and better prognosis of pancreatic cancer (pc) in patients with type 2 diabetes, but the mechanism of metformin's pc growth inhibition in the context of a prediabetic state is unknown. |
| PubMedID- 23207610 | Additionally, recent studies suggest that anti-diabetic medications may modulate the risk of pancreatic cancer in type 2 diabetes. |
| PubMedID- 23663483 | Almost 80% of pancreatic cancer patients present with either new-onset type 2 diabetes or impaired glucose tolerance at the time of diagnosis [9,10]. |
| PubMedID- 24641303 | Aims: it has been reported that glucagon-like peptide-1 (glp-1) agents are associated with an increased risk of pancreatic cancer in patients with type 2 diabetes. |
| PubMedID- 24837144 | Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. |
| PubMedID- 22015968 | Objectives: type 2 diabetes is associated with increased pancreatic cancer risk; however, the nature of this relationship is not clear. |
| PubMedID- 24662521 | At the time of diagnosis, almost 80% of pancreatic cancer patients present with new-onset type 2 diabetes (t2d) or impaired glucose tolerance. |
| PubMedID- 25556126 | For sensitivity analysis, we first repeated the analysis after excluding rate ratios that had an assigned fasting blood glucose concentration over 7.0 mmol/l, the cut off for diagnosing diabetes, to assess whether the observed trend was mainly attributable to an increased rate of pancreatic cancer associated with type 2 diabetes and to exclude reverse causality from diabetes induced by pancreatic cancer. |
| PubMedID- 25275365 | We observed greater magnitude of hazard ratios (hrs) of pancreatic cancer for patients with type 2 diabetes along with acute alcoholic hepatitis, acute pancreatitis, cholecystitis, and gastric ulcer compared with patients without type 2 diabetes or counterpart comorbidity (hr: 1.36, 95% confidence interval (ci): 1.19-1.56; 1.74, 1.23-2.45; 9.18, 7.44-11.33; and 2.31, 1.98-2.70, respectively). |
Page: 1